Home › Research › Treatments
Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis
Şen SE.. medRxiv, 2025-12-30
Topic: Drug trials: efficacy and safety
Plain-language summary
These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers. Results From an estimated eligible population of 11,568 individuals with early-stage Alzheimer’s disease, annual budget impact in Year 5 ranged from €12.8 million (conservative: 3% uptake) to €89.6 million (optimistic: 20% uptake), with a base case estimate of €35.8 million (8% uptake).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Şen, S. E. (2025). Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis. medRxiv. https://doi.org/10.64898/2025.12.30.25343198
Vancouver
Şen SE. Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis. medRxiv. 2025. doi:10.64898/2025.12.30.25343198.
BibTeX
@article{sen2025-31859e76,
author = {Şen, S. E.},
title = {{Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer’s Disease in Ireland: A Model-Based Analysis}},
journal = {medRxiv},
year = {2025},
doi = {10.64898/2025.12.30.25343198},
url = {https://doi.org/10.64898/2025.12.30.25343198}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers.
- Results From an estimated eligible population of 11,568 individuals with early-stage Alzheimer’s disease, annual budget impact in Year 5 ranged from €12.8 million (conservative: 3% uptake) to €89.6 million (optimistic: 20% uptake), with a base case estimate of €35.8 million (8% uptake).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants11,568
- Effect size0.05% to 0.33%
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 21 of the 62 points we could judge it on, which is 34 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 11,568 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 21 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 21 of the 62 points we could judge it on is 34 out of 100. |
| Total | 34 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “economic”
265 studies in the library carry the topic tag “economic”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.